The trial realized each its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically important and outstanding enhancements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without worsening of liver fibrosis in people with MASH when compared to placebo.1Mounjaro may be used as a singl